Dual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes
Grant Award Details
Grant Type:
Grant Number:
DISC2-12124
Investigator(s):
Name:
Type:
PI
Disease Focus:
Human Stem Cell Use:
Award Value:
$250,000
Status:
Closed
Progress Reports
Reporting Period:
Year 1
Grant Application Details
Application Title:
Dual angiogenic and immunomodulating nanotechnology for subcutaneous stem cell derived islet transplantation for the treatment of diabetes
Public Abstract:
Research Objective
Functional human islet like organoids differentiated from human pluripotent stem cells.
Impact
Providing the immediate cell therapeutic candidate for clinical trial of diabetic patients.
Major Proposed Activities
Functional human islet like organoids differentiated from human pluripotent stem cells.
Impact
Providing the immediate cell therapeutic candidate for clinical trial of diabetic patients.
Major Proposed Activities
- Fabrication and characterization of the injectable immunomodulating and pro-angiogenic material components: HA hydrogel, heparin nanoparticles and VEGF clusters.
- Generation of human islet like organoids from pluripotent stem cells for subcutaneous transplantation
- Subcutaneous HILOs transplantation in pre-vasculature site in NOD-SCID mice.
- Subcutaneous PD-L1 expressing HILOs transplantation in pre-vasculature site in Hu-PBMC-NSG mice
Statement of Benefit to California:
The cell and technology products proposed by this diabetes therapeutic study will significantly improve future diabetes treatments in the State of California, particularly benefiting vulnerable populations, such as Hispanics, African-Americans, men, older populations, homeless individuals, and those of lower socioeconomic status. Additionally, this proposed research may create greater research employment opportunities in the South Bay, a region within Los Angeles County.
Publications
- Front Cell Dev Biol (2022): Adapting Physiology in Functional Human Islet Organogenesis. (PubMed: 35557947)
- Front Endocrinol (Lausanne) (2021): Advances in Pancreatic Islet Transplantation Sites for the Treatment of Diabetes. (PubMed: 34589059)
- Gastroenterology (2022): Estrogen-Related Receptor gamma Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism. (PubMed: 35461826)
- Front Endocrinol (Lausanne) (2021): Immune Protection of Stem Cell-Derived Islet Cell Therapy for Treating Diabetes. (PubMed: 34447354)
- Int J Mol Sci (2022): Stem Cell-Derived Islets for Type 2 Diabetes. (PubMed: 35563490)
